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Abstract
Background: Palivizumab has been shown to decrease the incidence of hospitalization due to respiratory syncytial
virus (RSV) in infants at risk of severe RSV disease. We examined the association between compliance with
palivizumab dosing throughout the RSV season and risk of RSV-related hospitalization in clinical practice.
Methods: Subjects who were born and discharged from the hospital before the RSV season and received ≥1
palivizumab dose during their first RSV season were identified from a large US commercial health insurance
database between 01/01/03 and 12/31/09. Subjects were deemed compliant if they received ≥5 palivizumab doses
without gaps (>35 days) and their first dose was received by November 30. RSV-related hospitalizations were
identified using ICD-9-CM diagnosis codes and examined over 2 observation periods: post-index dose and RSV
season. A Cox proportional hazard model was used to evaluate the association between non-compliance and
RSV-related hospitalization.
Results: Of the 5,003 subjects who received palivizumab, 62% were deemed non-compliant. Non-compliant
subjects had significantly higher unadjusted rates of RSV-related hospitalizations compared to compliant subjects
during both observation periods (post-index: 6.1 vs. 2.8 per 100 infant seasons, p < 0.001; RSV season: 5.9% vs. 2.3%;
p < 0.001). In multivariate analyses, non-compliance was significantly associated with higher risk of RSV-related
hospitalization (HR = 2.01; p < 0.001). Of the 225 RSV-related hospitalizations observed during the RSV season,
61 (27%) occurred before the first dose of palivizumab.
Conclusions: Subjects who did not receive monthly dosing of palivizumab throughout the RSV season had
significantly higher rates of RSV-related hospitalizations. The RSV-related hospitalizations prior to the first dose of
palivizumab suggest some dosing was started too late.
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Background
Respiratory syncytial virus (RSV) is recognized as the
leading cause of serious lower respiratory tract disease in
infants and children [1-6]. Conditions associated with a
high risk for serious RSV disease include preterm birth
(≤35 weeks gestational age [wGA]); chronic lung disease
of prematurity (CLDP)/bronchopulmonary dysplasia (BPD]);
hemodynamically significant congenital heart disease (CHD);
immunodeficiency; and congenital abnormalities of the air-
ways or neuromuscular diseases [7-9].
Palivizumab is a humanized murine monoclonal antibody
that is approved by the US Food and Drug Administration
(FDA) for the prevention of severe respiratory tract
disease caused by RSV in children with BPD, infants
with a history of premature birth (≤35 wGA), and
children with hemodynamically significant CHD. The
FDA-approved dose is 15 milligrams per kilogram
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administered via intramuscular injection every 28–30 days
throughout RSV season. Randomized controlled clinical
trials of palivizumab versus placebo have shown a reduc-
tion in the incidence of hospitalization due to severe
RSV disease by approximately 40%-80% in high-risk
premature infants and certain children with CLD or
CHD [7,10]. The efficacy of palivizumab at doses
<15 mg per kg, or of dosing less frequently than
monthly throughout the RSV season, has not been
established.
The key objective of this analysis was to examine the
association between compliance with palivizumab and




The study used the Optum Research database, which
contains de-identified medical and pharmacy claims for
a geographically diverse and representative US privately
insured population. Enrollees’ claims covered the period
from May 01, 2003 through April 30, 2009. All data were
accessed using HIPAA [11]-compliant protocols. Be-
cause this study did not involve the collection, use, or
transmittal of individually identifiable data, Institutional
Review Board review or approval was not required.
Study sample
Commercially insured members with medical and
pharmacy benefits who received at least 1 dose of
palivizumab (identified with Current Procedural
Terminology/Healthcare Common Procedure Coding
System codes 90378, C9003, S9562; and National
Drug Code identifiers in pharmacy claims) between
October and April 2003–2009 were eligible for inclu-
sion. Eligible subjects were in their first year of life
with continuous enrollment in the health plan from
their date of birth through April 30 of the following year.
Inpatient claims do not capture hospital-administered
drugs including doses of palivizumab that would be
provided at discharge to eligible infants during the
RSV season. To ensure the ability to clearly identify all
doses, infants born during the RSV season (October 1 –
April 30) were excluded from the study. Claims were
analyzed from birth through April 30 of the following
year.
The date of the first palivizumab claim after October 1
was defined as the index date. The pre-index period was
defined as the date of birth to the index date. We de-
fined two observation periods for RSV outcomes. The
first was the post-index period, defined as the index date
through April 30 of the following year. The second was
the RSV season, defined as October 1 through April 30
of the following year (Figure 1).
High-risk populations
High-risk populations were defined as: infants <33 wGA;
infants between 33 and 36 wGA; infants with CLD; and
infants with hemodynamically significant CHD. Gesta-
tional age was defined using International Classification
of Diseases, Ninth Revision, Clinical Modification (ICD-
9-CM) diagnosis code 765.2x. Subjects with CLD were
identified through medical claims with a diagnosis code
for CLD and either a pharmacy claim for CLD medica-
tions (bronchodilators and/or diuretics), or a claim for
oxygen use during the pre-index period. Subjects with
CHD were identified through a medical claim with a
diagnosis code for CHD and a pharmacy claim for a
CHD medication during the pre-index period. High-risk
categories were not mutually exclusive groups.
Outcome measures
The total number of palivizumab doses received during
the RSV season was recorded for each subject along
with the calendar month of the index dose and the
average and maximum number of days between each
dose received. Subjects were deemed compliant if
they received ≥5 doses of palivizumab with no gaps
(>35 days) between doses, and they received their index
dose by November 30.
The major outcome of interest was RSV-related hospi-
talizations, identified using RSV-specific diagnosis codes
(079.6, 466.11, 480.1) and RSV-like diagnosis codes
defined as unspecified bronchitis (466.0), bronchiolitis
(466.19), viral pneumonia (480.9), bronchopneumonia
(485), and pneumonia (486) that occurred during the
RSV season [12-14]. RSV-like diagnoses were excluded if
there were any claims for influenza or other bacterial
pneumonia (481, 482.xx, 487.x) within 3 days of the
RSV-like claim.
Pre-index clinical characteristics and healthcare utilization
were identified to control for potential confounding vari-
ables. To account for variable pre-index and post-index
periods, all healthcare utilization was calculated per sub-
ject per month.
Univariate analysis
All study variables were analyzed descriptively. Numbers
and percentages are provided for categorical variables.
Means, medians, and standard deviations are provided
for continuous variables. RSV-related hospitalizations for
the post-index period were calculated as rates per 100
infant seasons to adjust for the variable length of follow-
up time for each individual. Infant seasons were defined
as the number of days in the follow-up (end of the sea-
son – date of first in-season injection +1) divided by 212
(the number of days in the season). Comparisons were
made using t-tests for continuous variables and chi-
squared tests for categorical variables.
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Multivariate analysis
Multivariate analysis of RSV-related hospitalizations in
the post-index period was conducted using a Cox pro-
portional hazard regression. Parametric regression sur-
vival models were based on maximum likelihood
estimation. Covariates were entered into the model in
variable blocks; if one variable from the block was in-
cluded, then all variables in the block were included.
The first model examined only non-compliance vs.
hospitalization. Chronic lung disease, CHD, and gesta-
tional age were added to subsequent models. All variables
in the final model were tested for collinearity to ensure
the accuracy of the parameter estimates. The results of
Cox proportional hazard regression are presented as haz-
ard ratios associated with each independent variable.
To understand the stability of the results, the final
model was run in population subsets to examine
whether the direction or magnitude of the relationship
between non-compliance and RSV-related hospitaliza-
tions changed in specific population cohorts. The sub-
sets examined were: subjects with CHD, subjects with
CLD, subjects whose index dose was received in either
October or November, subjects without a pre-index
palivizumab dose, subjects categorized by RSV season
(e.g., Oct 1, 2003 through April 30, 2004 season), and
subjects categorized by birth month.
Results
Pre-index clinical characteristics
A total of 5,003 subjects met study inclusion criteria.
Over half (57.1%) were single births, with slightly more
males (54.7%) than females (Table 1). The subjects’ birth
months were evenly distributed across May through
August with approximately 21% born in each month
except for a slightly smaller proportion (13.1%) born in
September.
Approximately two-thirds (66.7%) of the total sample
had low birth weight (<2500 g), and a third (36.1%) had
at least 1 prespecified comorbidity. The most common
comorbidities were retinopathy of prematurity (24.1%),
intraventricular hemorrhage (7.9%), and congenital air-
way anomalies (3.8%) (Table 1).
Palivizumab utilization
Overall, 75% of subjects received at least 5 palivizumab
doses, and the mean (SD) number of days between doses
was 31.6 (8.5). Eighty-seven percent of the index
palivizumab doses were given in October (58.7%) or
November (28.2%) (Figure 2). On average, subjects had
1.5 dosing gaps, with a mean (SD) gap of 9.4 days (11.4)
or 44.4 days since prior dose.
Clinical characteristics by compliance status
Thirty-eight percent of subjects were deemed compliant.
When compared to non-compliant subjects, a higher
percentage of compliant subjects were twins (31.3% vs.
26.8%; p ≤ 0.001) and had low birth weight (69.9% vs.
64.7%; p ≤ 0.001). There was no significant difference in
the proportion of patients with at least 1 pre-existing
comorbidity (p = 0.603). While uncommon, a signifi-
cantly higher proportion of non-compliant subjects
had a diagnosis of immunodeficiency state (0.65% vs.
0.16%; p = 0.013), while a significantly higher propor-
tion of compliant subjects had a diagnosis of cystic fibrosis
(1.57% vs. 0.97%; p = 0.059 [Table 1]). Both groups had
similar proportions of subjects with retinopathy of prema-
turity. A significantly higher proportion of compliant
subjects had a NICU stay at birth compared to non-
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Figure 1 Study periods.
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Table 1 Pre-index demographic and clinical characteristics
Demographic Total Compliant Non-compliant p-value
(N = 5,003) (N = 1,912) (N = 3,091)
Gender
Male n 2,738 1,046 1,692
% 54.73 54.71 54.74 0.982
Birth Number
All stillborn siblings n 25 9 16
% 0.5 0.47 0.52 0.819
Single birth n 2,857 1,049 1,808
% 57.11 54.86 58.49 0.012
Twin n 1,427 599 828
% 28.52 31.33 26.79 <0.001
Multiple birth n 256 115 141
% 5.12 6.01 4.56 0.023
Other n 4 1 3
% 0.08 0.05 0.1 0.586
Not available n 434 139 295
% 8.67 7.27 9.54 0.005
Clinical Characteristics
Low birth weight (<2500 g) n 3,337 1,337 2,000
% 66.7 69.93 64.7 <0.001
<33 wGA n 1,895 755 1,140
% 37.8 39.5 36.9 0.065
33-36 wGA n 2,201 854 1,347
% 44 44.7 43.6 0.452
NICU
NICU hospitalization n 3,830 1,523 2,307
% 86.79 88.19 85.89 0.028
NICU hospitalization length n 4,413 1,727 2,686
mean 15.79 15.93 15.7 0.714
SD 20.38 20.23 20.48
median 8 8 8
Birth Hospitalization
Length of birth hospitalization n 4,413 1,727 2,686
mean 25.4 26.15 24.92 0.062
SD 21.44 20.98 21.72
median 19.00 20.00 18.00
Comorbidity
Immunodeficiency state n 23 3 20
% 0.46 0.16 0.65 0.013
Trisomy 21 n 119 44 75
% 2.38 2.3 2.43 0.778
Intraventricular hemorrhage n 397 158 239
% 7.94 8.26 7.73 0.499
Necrotizing enterocolitis n 114 35 79
% 2.28 1.83 2.56 0.095
Hydrocephalus n 56 19 37
% 1.12 0.99 1.2 0.507
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compliant subjects (88.2% vs. 85.9%; p = 0.028). There was
no statistical difference between compliance groups with
regard to time spent in the NICU (p = 0.714) or length of
birth hospitalization stays (p = 0.062).
RSV-related outcomes by compliance status
Among the total sample (n = 5,003), 164 subjects (3.3%)
had at least 1 RSV-related hospitalization during the
post-index period. Non-compliant subjects had signifi-
cantly higher unadjusted rates of RSV-related hospitali-
zations (6.1 per 100 infant RSV seasons vs. 2.8 per 100
infant RSV seasons; p < 0.001 [Figure 3]). This difference
was seen for both RSV and RSV-like hospitalizations
(Table 2).
A total of 225 subjects (4.5%) had at least 1 RSV-
related hospitalization during the entire RSV season.
Table 1 Pre-index demographic and clinical characteristics (Continued)
Periventricular leukomalacia n 54 21 33
% 1.08 1.1 1.07 0.919
Retinopathy of prematurity n 1,206 452 754
% 24.11 23.64 24.39 0.545
Sensorineural hearing loss n 66 20 46
% 1.32 1.05 1.49 0.183
Severe neuromuscular disorders n 127 48 79
% 2.54 2.51 2.56 0.921
Cerebral palsy n 12 3 9
% 0.24 0.16 0.29 0.345
Cystic fibrosis n 60 30 30
% 1.2 1.57 0.97 0.059
CMV n 8 0 8
% 0.16 0 0.26 0.026
Chromosomal syndrome n 168 58 110
% 3.36 3.03 3.56 0.316
Congenital anomalies of the airways n 192 65 127
% 3.84 3.4 4.11 0.205
Pre-index home medical equipment n 1,449 548 901
% 28.96 28.66 29.15 0.712
Post-index home medical equipment n 1,115 430 685
% 22.29 22.49 22.16 0.786
Oxygen use n 392 144 248










































Figure 2 Timing of first palivizumab dose by compliance status.
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Non-compliant subjects also had significantly higher un-
adjusted rates of RSV-related hospitalizations (5.9% vs.
2.3%; p < 0.001). This difference was seen for both RSV
and RSV-like hospitalizations (Table 2). Twenty-seven
percent of all RSV-related hospitalizations captured in the
study occurred prior to the index dose of palivizumab.
The non-compliant group had a larger proportion of hos-
pitalizations prior to the index dose than the compliant
group (24.9% vs. 2.2% of RSV-related hospitalizations,
respectively). For the main analysis (post-index period),
the 61 RSV-related hospitalizations that occurred prior
to the first dose of palivizumab were excluded.
There were no significant differences between non-
compliant and compliant subjects with regard to other
respiratory-related hospitalizations during the post-index
period (0.6 vs. 0.3 per 100 infant RSV seasons; p = 0.285)
or during the RSV season (0.3% vs. 0.5%; p = 0.134).
Multivariate analysis
To control for collinearity in the model, a correlation
matrix was created to examine the relationship between
all of the covariates. There was a weak correlation be-
tween low birth weight and unknown gestational age, as
well as weak associations between NICU stays and mul-
tiple births. No other significant associations were noted;
therefore, no covariates were excluded from the model
due to collinearity.
After controlling for potential confounders, the Cox
proportional hazard model demonstrated that non-
compliance was significantly associated with a higher risk
of RSV-related hospitalization (HR = 2.01 [95% CI: 1.39 –
2.89]; Table 3). Having CLD, at least 1 prespecified co-
morbidity during the pre-index period, a pre-index
RSV-related hospitalization, and a pre-index ED visit































Figure 3 Unadjusted RSV-related hospitalization rate for post-index period by type of hospitalization and compliance status.
Table 2 Proportion of RSV hospitalizations by diagnosis and observation period
Total Compliant Non-compliant p-value
(N = 5,003) (N = 1,912) (N = 3,091)
Post-index Period
RSV hospitalization n 57 7 50
% 1.14 0.37 1.62 <0.001
RSV-like hospitalization n 119 33 86
% 2.38 1.73 2.78 0.017
Full RSV Season
RSV hospitalization n 88 9 79
% 1.76 0.47 2.56 <0.001
RSV-like hospitalization n 154 38 116
% 3.08 1.99 3.75 <0.001
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RSV-related hospitalization, while being part of a multiple
birth and having received a pre-index palivizumab dose
were significantly associated with a lower risk of RSV-
related hospitalization (Table 2).
Sensitivity analyses
In the majority of sensitivity analyses, there was an asso-
ciation between non-compliance and an increased risk
of RSV-related hospitalization although the results were
not always statistically significant (Figure 4).
As an additional analysis, we examined a logistic re-
gression model for the full RSV season using the same
variables as those used in the Cox proportional hazard
model. Using this approach, non-compliance was signifi-
cantly associated with increased odds of RSV-related
hospitalization (OR = 2.45 [95% CI: 1.73 – 3.46]).
Discussion
The aim of this study was to examine the association be-
tween compliance with palivizumab and RSV-related
hospitalizations in commercially insured infants. In our
study, non-compliant subjects had higher unadjusted
rates of RSV-related hospitalizations than compliant in-
fants. The multivariate analysis found that, after adjusting
for potential confounding factors, non-compliant subjects
were significantly more likely to have an RSV-related
hospitalization than compliant subjects. While our ana-
lysis cannot determine causality, it identifies an association
that should be further explored.
This is one of the largest published studies in a com-
mercially insured population to examine the association
between compliance with palivizumab and RSV-related
hospitalizations. Previous studies have examined the
Table 3 RSV-related hospitalization risk
Variable Post-index (Cox)
Hazard ratio (95% CI) P-value*
Palivizumab non-compliance (ref. compliance) 2.007 (1.392 - 2.894) <0.001
Chronic lung disease 2.035 (1.262 - 3.281) 0.004
Congenital heart disease 1.24 (0.778 - 1.978) 0.366
33-36 wGA (ref. < 33 wGA) 0.983 (0.634 - 1.522) 0.937
Unknown wGA (ref. < 33 wGA) 1.966 (1.206 - 3.206) 0.007
Male gender (ref. female) 1.152 (0.841 - 1.578) 0.378
Geographic region – Northeast (ref. South) 0.813 (0.469 - 1.407) 0.459
Geographic region – Midwest (ref. South) 1.226 (0.854 - 1.759) 0.269
Geographic region – West (ref. South) 0.862 (0.526 - 1.414) 0.557
Index year – 2004 (ref. 2003) 1.027 (0.618 - 1.706) 0.919
Index year – 2005 (ref. 2003) 0.893 (0.528 - 1.513) 0.675
Index year – 2006 (ref. 2003) 0.724 (0.415 - 1.262) 0.254
Index year – 2007 (ref. 2003) 0.827 (0.463 - 1.476) 0.520
Index year – 2008 (ref. 2003) 0.922 (0.534 - 1.591) 0.769
Birth number – multiple birth (ref. single birth) 0.418 (0.267 - 0.655) <0.001
Birth number – unknown (ref. single birth) 0.656 (0.313 - 1.373) 0.263
Pre-index palivizumab use 0.507 (0.276 - 0.933) 0.029
NICU hospitalization at birth (ref. no NICU) 1.354 (0.807 - 2.274) 0.251
Unknown NICU hospitalization at birth (ref. no NICU) 0.875 (0.312 - 2.457) 0.800
Pre-index ambulatory visit 0.677 (0.162 - 2.827) 0.593
Pre-index emergency department visit 1.746 (1.231 - 2.477) 0.002
Pre-index inpatient hospitalization 1.258 (0.387 - 4.085) 0.703
Pre-index RSV-related hospitalization 3.059 (1.574 - 5.942) 0.001
Any pre-index comorbid condition 2.003 (1.411 - 2.843) <0.001
Low birth weight (<2500 g) 0.906 (0.598 - 1.373) 0.643
Birth month: May (ref. Sept) 1.019 (0.587 - 1.769) 0.947
Birth month: June (ref. Sept) 0.7 (0.394 - 1.244) 0.224
Birth month: July (ref. Sept) 0.794 (0.456 - 1.384) 0.416
Birth month: August (ref. Sept) 0.713 (0.405 - 1.256) 0.242
*Values that reflect statistical significance at P<0.05 are in boldface.
CI, Confidence interval.
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predictors of compliance with palivizumab, RSV-related
hospitalization rates among high-risk infants, and costs and
resource use associated with RSV-related hospitalization
and/or palivizumab [15-22]. However, we are unaware of
other published studies using multivariate analyses to test
the association between compliance with palivizumab
use and RSV-related hospitalization in a commercially
insured population.
In a retrospective claims analysis, Diehl et al. [21]
examined the impact of palivizumab compliance on
respiratory-related and RSV-specific hospitalizations.
Overall, they found 30% of the 245 infants included
in their study to be compliant with palivizumab. Un-
like the current study, the authors found no signifi-
cant differences in respiratory-related or RSV-specific
hospitalizations between the compliance groups. Their
study differs from ours in a number of ways. Their
study was an exploratory and descriptive analysis and
they did not include multivariate analyses [21]. They
analyzed only one season of data with a substantially
smaller sample size; and their study sample contained
several populations not included in our study such as
Medicaid-insured infants, second-season infants, and
in-season births, in whom compliance is more diffi-
cult to assess.
Despite a large number of subjects receiving 4 or more
doses, our study showed significant differences in RSV-
related hospitalization rates between compliance groups.
On average, subjects had 1.5 dosing gaps (time between
doses >35 days) with a mean gap length of 9.4 days or
44.4 days since the previous dose, suggesting that dosing
gaps do not need to occur often or be lengthy to be associ-
ated with an increased risk of RSV-related hospitalization.
Although a relatively small time period, gaps of approxi-
mately 15 days would be expected to lead to significantly
lower serum levels of palivizumab [23]. Results published
by the Palivizumab Outcomes Registry Group [13] dem-
onstrated similar results. The Registry study assessed com-
pliance and RSV-related hospitalization rates in high-risk
children receiving palivizumab at home vs. an outpatient
setting; the investigators found significantly lower
odds of an RSV-related hospitalization in infants re-
ceiving all doses within 35 days of previous dose com-
pared with those who did not [16]. A study by Golombek
et al. [18] also examined compliance among infants





























Figure 4 Hazards for RSV-related hospitalization associated with palivizumab non-compliance for select population subsets*.
*Data representing CLD have been omitted from this graph due to small sample size and large confidence interval (3.3 – 79.9).
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and found that better compliance with home injections
was associated with a decrease in the rate of RSV related
hospitalizations.
RSV-related hospitalizations prior to the index
palivizumab dose occurred in both groups, with signifi-
cantly more hospitalizations occurring before the index
dose in the non-compliant group. The timing of the RSV
season varies considerably by region [24], and the pres-
ence of early-season hospitalizations underlines the need
for effective local monitoring of RSV activity and ex-
pediting administration of the first outpatient dose of
palivizumab for eligible infants and children. While
we selected a palivizumab start date of November 30
to define compliance, it is not possible to determine
the actual RSV season start from claims data. Where
available, it is best to use local virology and to start
dosing infants at high risk of serious RSV disease as
early in the season as possible. Likewise, close moni-
toring should be performed at the end of the season
to note when it is appropriate to stop dosing.
Limitations
Interpretation of our study results must take into ac-
count the limitations of the study design and the use of
healthcare claims. Administrative claims data are col-
lected for payment purposes and not research; therefore,
the degree to which claims accurately describe an indi-
vidual’s medical history is limited. Claims data also do
not contain information on behavioral or social risk fac-
tors. Information regarding the subjects’ race, ZIP code
level data, and the parents’ socioeconomic status was
also unavailable. The association between compliance
and RSV-related hospitalization may be confounded by
risk factors that we cannot account for in our model.
We relied on diagnosis codes to determine high-risk
cohorts. For gestational age, the ICD-9-CM codes are
defined in 2-week segments (e.g., 33–34 wGA, 35–36
wGA, etc.). We used a combination of diagnosis codes
and medication use to define CLD. CLD is broadly de-
fined as any pulmonary condition resulting from a neo-
natal respiratory disorder. BPD is a form of CLD, but
not all CLD is BPD. CLD is often used interchangeably
with BPD. Therefore, some of the identified high-risk
cohorts may include infants outside of the labeled in-
dication for palivizumab (e.g., 36 wGA subjects in the
33–36 wGA cohort and non-CLD/BPD subjects in the
CLD cohort).
Given hospital coding practices, palivizumab doses ad-
ministered during a hospitalization were not captured.
Therefore, infants born during the RSV season, who are
often at highest risk of serious RSV disease, were ex-
cluded from the study. Omission of this group may limit
the ability to generalize study results to all infants re-
ceiving prophylaxis.
RSV is often not tested for during the season; there-
fore, claims may result in a non-specific ICD-9 diagnosis
code. A recent analysis [14] found that only 20% of chil-
dren with a bronchiolitis episode were tested for RSV, of
which half were positive, highlighting the potential
underestimation of RSV when solely relying on RSV
diagnostic codes. The authors estimated that if the RSV
positivity rate among untested bronchiolitis was conser-
vatively half that of infants who were tested, this would
result in an underestimation of RSV disease of ~65%. In
an attempt to capture all cases, we included RSV-like
hospitalizations where it was not possible to confirm an
RSV diagnosis. The use of non-specific diagnosis codes
may have included hospitalizations unrelated to RSV.
We attempted to mitigate potential overestimation by ex-
cluding cases where influenza or bacterial pneumonia was
diagnosed within 3 days of the RSV-like hospitalization.
This is similar to the methodology the US Centers for
Disease Control and Prevention uses to estimate RSV bur-
den [25]. While overestimation may have occurred, it is
unlikely this bias would impact one cohort more than the
other. Since all infants in the analysis were receiving
palivizumab, their physicians had identified them as being
at high-risk for serious RSV disease and eligible for
prophylaxis. Therefore, we do not anticipate the likelihood
of testing and/or being given an RSV-specific diagnoses
would differ between compliant and non-compliant
infants. We also saw consistent trends for an associ-
ation between increased risk of hospitalization and
non-compliance when using both RSV-specific and
RSV-related diagnosis codes. It also is assuring that
both groups had no significant differences in other
respiratory hospitalizations as palivizumab should not
affect those hospitalizations.
Our main analysis focused on RSV outcomes that oc-
curred after the first palivizumab dose, defined as the
post-index period. In this observation period, there may
be differences in RSV exposure time between the com-
pliant and non-compliant cohorts. For example, compli-
ant infants could have the number of days at risk
inflated due to adding days early in the season with a
lower exposure risk. While non-compliant infants have
fewer days at risk, they could have a higher percentage
of days in the “peak” RSV period. One of the limitations
to using administrative insurance claims is the inability
to determine when RSV began circulating in the com-
munities of the subjects included in our analysis. In
order to address the potential issues related to the vari-
able exposure/follow-up, we also looked at RSV hospital-
izations for a uniform observation period (October 1 to
April 30). In both analyses, we saw a statistically signifi-
cant increased risk/odds of RSV-related hospitalizations
associated with non-compliance. Future analyses exam-
ining the association between compliance and RSV
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hospitalization may want to consider collecting data on
RSV circulation to adjust for exposure.
In the full RSV season analysis, over a quarter of all
RSV-related hospitalizations occurred prior to the first
dose of palivizumab. Starting dosing late contributes to
non-compliance, so we felt it was important to include
hospitalizations that occurred prior to initiation of
palivizumab prophylaxis in the analysis. However, hospi-
talizations prior to the first dose of palivizumab do not
tell us the impact of partial prophylaxis on RSV hospital-
izations once dosing has been started. For this reason,
we chose the post-index observation period as our pri-
mary analysis. In the post-index period, we only exam-
ined RSV-related hospitalizations that occurred after
infants had received their first dose of palivizumab and
excluded hospitalizations (n = 61) that occurred prior to
the first dose. We did not censor or exclude infants who
had an RSV hospitalization prior to the first dose of
palivizumab as children can become infected and hospi-
talized with RSV multiple times in one season. In both
the full season and post-index period, we saw a statisti-
cally significant increased risk/odds of RSV-related hos-
pitalizations associated with non-compliance.
Finally, our data pertain to a commercially insured
population. Therefore, the results are primarily applic-
able to commercially insured infants and may not be
generalizable to other populations such as Medicaid or
uninsured infants.
Conclusions
To our knowledge, this is one of the largest studies in a
commercially insured population to examine the associ-
ation between palivizumab compliance and RSV-related
hospitalizations in a clinical setting. In our study,
non-compliant subjects had higher unadjusted rates
of RSV-related hospitalization than compliant subjects
and non-compliance was associated with a signifi-
cantly higher risk of RSV-related hospitalization after
adjusting for potential confounders.
The association between compliance and RSV-related
hospitalization and the occurrence of hospitalizations
prior to the first palivizumab dose suggest the importance
of getting a first dose early in the RSV season and monthly
dosing throughout the season. Future analyses should con-
sider other predictors of compliance such as behavioral
and social risk factors when examining the association
between compliance and RSV-related hospitalization.
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